AL amyloidosis


Webinar: “Progress in Amyloidosis: 2022”

Webinar: “Progress in Amyloidosis: 2022”

July 2022 Live Webinar Event

Please join us for our webinar event presented by Dr. Jeffrey Zonder

on

July 13, 2022, at 2:30 pm ET

Register Here

Dr. Zonder will describe recent advances in the management of AL amyloidosis; review approved therapies for ATTR amyloidosis and how they work, and discuss new classes of agents designed to help remove existing amyloid deposits.

Jeffrey Zonder, MD, is a Professor in the Departments of Oncology at the Barbara Ann Karmanos Cancer Institute (KCI) and Wayne State University School of Medicine. He is the Leader of the KCI Multiple Myeloma and Amyloidosis Multidisciplinary Team and Co-Leader of the Molecular Therapeutics Program. He is a member of the Steering Committee of the Multiple Myeloma Research Consortium and a medical advisor for the Amyloidosis Support Groups Networks. Dr. Zonder is a member of the International Myeloma Working Group, the International Myeloma Society, and the International Society of Amyloidosis.  He is a member of the Southwest Oncology Group’s (SWOG) Barlogie-Salmon Myeloma Committee. Dr. Zonder has authored or co-authored numerous original research papers, review articles, book chapters, and research abstracts on myeloma and amyloidosis.

He completed a fellowship in hematology-oncology at Wayne State University and his medical residency at the University of Rochester, New York.  He received his medical degree from Wayne State University School of Medicine.

Sponsored by:


Amyloidosis Foundation Announces 2022 Research Grant Recipients

Amyloidosis Foundation Announces 2022 Research Grant Recipients

We are pleased to announce the funding of three new Junior Investigator Research Grants for 2022. The Amyloidosis Foundation Research Grants have been awarded to the following applicants:

K. H. Vincent Lau, MD of Boston University, Boston, MA. His research is titled “Evaluating Plasma Neurofilament Light Chain as an Early Biomarker for Polyneuropathy in V122I Hereditary Transthyretin Amyloidosis”.

Zainul S. Hasanali, MD, PhD of University of Pennsylvania, PA.  His study is “Targeting amyloidosis through study of calcium dependent endoplasmic reticulum resident protein folding chaperones and their effect on antibody production in plasma cells”.  

Taxiarchis Kourelis, MD of Mayo Clinic, Rochester, MN. His research is titled “Characterizing the role of the tissue immunome in the pathogenesis of renal AL amyloidosis”.

The Amyloidosis Foundation has awarded over $2 million to research since the inception of the grant program in 2005.

Click here for photos and to read more about their proposals.

Congratulations!


Fall Webinar Recording: Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Fall Webinar Recording: Established and Emerging Treatment Strategies for AL Amyloidosis in 2021

Listen to our latest webinar that was recorded on September 14, 2021. Presented by Heather Landau, MD who is a hematologist-oncologist and the Director of the Amyloid Program at Memorial Sloan Kettering (MSK) Cancer Center focused on increasing access to novel, effective therapies in AL amyloidosis and has investigated drugs at all stages of development.  She has conducted multiple investigator-initiated clinical trials exploring novel agents and approaches, including consolidation and maintenance strategies in high-risk patients.  She led the development of MSK’s Outpatient Transplant Service and is studying innovative ways to optimize high-dose therapy and transplant care.

LISTEN HERE


DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.1 DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with AL amyloidosis.

Read the complete press release here.